CA2319542A1 - Traitement des troubles de la sexualite chez certains groupes de patients - Google Patents

Traitement des troubles de la sexualite chez certains groupes de patients Download PDF

Info

Publication number
CA2319542A1
CA2319542A1 CA002319542A CA2319542A CA2319542A1 CA 2319542 A1 CA2319542 A1 CA 2319542A1 CA 002319542 A CA002319542 A CA 002319542A CA 2319542 A CA2319542 A CA 2319542A CA 2319542 A1 CA2319542 A1 CA 2319542A1
Authority
CA
Canada
Prior art keywords
sexual dysfunction
patient groups
treatment
certain patient
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002319542A
Other languages
English (en)
Other versions
CA2319542C (fr
Inventor
Neal R. Cutler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RT ALAMO VENTURES Inc
Original Assignee
Rt Alamo Ventures, Inc.
Neal R. Cutler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/071,457 external-priority patent/US6110489A/en
Priority claimed from US09/166,703 external-priority patent/US6194433B1/en
Priority claimed from US09/175,395 external-priority patent/US6132753A/en
Priority claimed from US09/260,099 external-priority patent/US6132757A/en
Priority claimed from US09/262,715 external-priority patent/US6187790B1/en
Application filed by Rt Alamo Ventures, Inc., Neal R. Cutler filed Critical Rt Alamo Ventures, Inc.
Publication of CA2319542A1 publication Critical patent/CA2319542A1/fr
Application granted granted Critical
Publication of CA2319542C publication Critical patent/CA2319542C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Quinoline Compounds (AREA)
CA002319542A 1998-05-01 1999-04-30 Traitement des troubles de la sexualite chez certains groupes de patients Expired - Fee Related CA2319542C (fr)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US09/071,457 1998-05-01
US09/071,457 US6110489A (en) 1998-05-01 1998-05-01 Use of quinolines and quinolones to treat male erectile dysfunction
US09/166,703 1998-10-05
US09/166,703 US6194433B1 (en) 1998-10-05 1998-10-05 Sexual dysfunction in females
US09/175,395 US6132753A (en) 1998-05-01 1998-10-19 Treatment of sexual dysfunction in certain patient groups
US09/175,395 1998-10-19
US09/260,099 US6132757A (en) 1998-05-01 1999-03-02 Treatment of sexual dysfunction in certain patient groups
US09/260,099 1999-03-02
US09/262,715 US6187790B1 (en) 1999-03-04 1999-03-04 Use of cilostazol for treatment of sexual dysfunction
US09/262,715 1999-03-04
PCT/US1999/009610 WO1999056666A1 (fr) 1998-05-01 1999-04-30 Traitement des troubles de la sexualite chez certains groupes de patients

Publications (2)

Publication Number Publication Date
CA2319542A1 true CA2319542A1 (fr) 1999-11-11
CA2319542C CA2319542C (fr) 2005-07-12

Family

ID=27535884

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002319542A Expired - Fee Related CA2319542C (fr) 1998-05-01 1999-04-30 Traitement des troubles de la sexualite chez certains groupes de patients

Country Status (7)

Country Link
EP (1) EP1079764A4 (fr)
JP (1) JP2002537231A (fr)
AU (1) AU3780699A (fr)
BR (1) BR9908716A (fr)
CA (1) CA2319542C (fr)
MX (1) MXPA00010254A (fr)
WO (1) WO1999056666A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6548490B1 (en) * 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6541487B1 (en) * 1998-05-01 2003-04-01 R.T. Alamo Ventures I, Llc PDE III inhibitors for treating sexual dysfunction
WO2002058703A2 (fr) * 2001-01-26 2002-08-01 R.T. Alamo Ventures I, Llc Traitement de troubles sexuels et de maladie cardio-vasculaire avec des enantiomeres quinolinone
US6727262B2 (en) 2002-03-01 2004-04-27 R.T. Alamo Ventures I, Llc Dichlorinated heterocyclic compounds and methods of synthesis
US6767914B2 (en) 2002-03-01 2004-07-27 R.T. Alamo Ventures I, Llc Fluorinated heterocyclic compounds and methods of synthesis
US6730790B2 (en) 2002-03-01 2004-05-04 R.T. Alamo Ventures I. Llc Chlorinated heterocyclic compounds and methods of synthesis
US7041677B2 (en) 2002-03-01 2006-05-09 R.T. Alamo Ventures I, Llc Use of monochloroflosequinan in the treatment of sexual dysfunction
GB0208704D0 (en) * 2002-04-16 2002-05-29 Futura Medical Dev Ltd Condom
TWI323660B (en) * 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener
TWI338583B (en) 2004-05-20 2011-03-11 Otsuka Pharma Co Ltd Solid pharmaceutical formulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
DE4117249C2 (de) * 1991-05-27 1998-05-14 Christian Dr Stief Linsidomin zur Behandlung erektiler Dysfunktionen
EP0651640A1 (fr) * 1992-07-21 1995-05-10 Knoll AG Utilisation de 7-fluoro-1-methyl-3-methylsulphinyl-4-quinolone dans le traitement de l'angine de poitrine
GB9301192D0 (en) * 1993-06-09 1993-06-09 Trott Francis W Flower shaped mechanised table
WO2000007595A1 (fr) * 1998-08-03 2000-02-17 Basf Corporation Utilisation de pyridinones pour traiter les dysfonctionnements sexuels

Also Published As

Publication number Publication date
EP1079764A1 (fr) 2001-03-07
BR9908716A (pt) 2000-11-21
JP2002537231A (ja) 2002-11-05
MXPA00010254A (es) 2002-08-06
WO1999056666A1 (fr) 1999-11-11
AU3780699A (en) 1999-11-23
WO1999056666A8 (fr) 2000-08-10
EP1079764A4 (fr) 2001-09-12
CA2319542C (fr) 2005-07-12

Similar Documents

Publication Publication Date Title
IL256054A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
WO2004019884A3 (fr) Agents et procedes pour stimuler la formation osseuse
CA2184916A1 (fr) Utilisation des facteurs de croissance des fibroblastes pour stimuler la croissance des os
HUT60630A (en) Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature
IL112664A0 (en) 4-amino derivatives of mycophenolic acid, their preparation and pharmaceutical compositions containing them
CA2373794A1 (fr) Compositions et utilisation d'et743 pour le traitement du cancer
CA2319542A1 (fr) Traitement des troubles de la sexualite chez certains groupes de patients
CA2294921A1 (fr) Levobupivacine et son utilisation
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
DE69521536T2 (de) Zusammensetzungen die G-CSF und ein TNF-Bindungsprotein enthalten
HUP9904317A3 (en) Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases
AU8020698A (en) Use of glucosamine and glucosamine derivatives for quick alleviation of itching or localized pain
HUP0302538A3 (en) 3,7-diazabicyclo[3.3.0]oczanes and their use in the treatment of cardiac arrhythmias, process for their preparation and pharmaceutical compositions containing them
DE69939075D1 (de) Pharmazeutische Zusammenstellung zur Vorbeugung und Behandlung von mit Zellkrankheiten des Augenhintergrundes zusammenhängenden Krankheiten
EP0744176A3 (fr) Médicaments pour inhiber les pertes osseuses
WO1999065475A3 (fr) Combinaison de phentolamine et apomorphine pour le traitement concernant les fonctions et les dysfonctionnements sexuels
EP0821969A3 (fr) Composition médicale contenant du TCF-II
CA2290739A1 (fr) Nouveaux sels de peptides bpc ayant une activite de protection de l'organisme, procede de preparation correspondant et leur utilisation en therapie
IL118833A (en) Sertraline for use as a medicament in the treatment of post-myocardial infarction patients
MA26648A1 (fr) Associations thérapeutiques pour le traitement de maladies osseuses, et procédé pour leur préparation.
WO2000078800A3 (fr) Compositions combinant la proteine de liaison de decorine et la proteine de surface externe et procedes correspondants
CA2097878A1 (fr) Agent therapeutique pour la neutropenie
UA32241A (uk) Спосіб лікування запалювальних процесів у експериментальних тварин
AU2002300509A1 (en) The Treatment of Sexual Dysfunction in Certain Patient Groups
RU93014293A (ru) Способ лечения хронического бронхита

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed